Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19176877 | 0.98 | LMNA (0.42) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL19176721 | 0.98 | LMNA (0.42) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL19573802 | 0.95 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL18427298 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1LMNAKDM4EALOX15 | |
| SCHEMBL19059408 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL18923249 | 0.84 | LMNA (0.42) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL22024919 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL20980158 | 0.84 | LMNA (0.42) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL18612675 | 0.84 | LMNA (0.42) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E | |
| SCHEMBL18468195 | 0.84 | LMNA (0.42) | SMN1; SMN2L3MBTL1LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2022-11-15 | — | — | US | disclosed |
| US-11071731-B2 | Allosteric modulators of the mu opioid receptor | Chiromics, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORTION | 2021-06-24 | — | — | US | disclosed |
| US-20200276177-A1 | Allosteric Modulators of the Mu Opioid Receptor | Chiromics, LLC (US) | 2020-09-03 | — | — | US | disclosed |
| US-9938294-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE HOLDINGS CORPORATION (US) | 2017-07-27 | — | — | US | disclosed |
| WO-2008024953-A2 | TRANSITION METAL-CATALYZED ALKYLATION OF C-H BONDS WITH ORGANOBORON REAGENTS | BRANDEIS UNIVERSITY (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024953-A2 | TRANSITION METAL-CATALYZED ALKYLATION OF C-H BONDS WITH ORGANOBORON REAGENTS | BRANDEIS UNIVERSITY (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | SMN1; SMN2 4578/4885L3MBTL1 1182/4885LMNA 3201/4885 |
| US-20200276177-A1 | Allosteric Modulators of the Mu Opioid Receptor | OPRM1, OPRK1, OPRD1 | SMN1; SMN2 1176/4885L3MBTL1 761/4885LMNA 4854/4885 |
| US-20170320895-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | SMN1; SMN2 905/4885L3MBTL1 2047/4885LMNA 491/4885 |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | SMN1; SMN2 4604/4885L3MBTL1 697/4885LMNA 3296/4885 |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | SMN1; SMN2 4578/4885L3MBTL1 1182/4885LMNA 3201/4885 |
| US-11071731-B2 | Allosteric modulators of the mu opioid receptor | OPRM1, OPRK1, OPRD1 | SMN1; SMN2 1176/4885L3MBTL1 761/4885LMNA 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.